Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Thursday. $123.96 million flowed into the stock on the tick-up and $230.58 million flowed out of the stock on the tick-down, for a money net flow of $106.62 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 5th highest net out-flow for the day. Johnson & Johnson traded up $0.53 for the day and closed at $139.89

A number of equities analysts recently weighed in on JNJ shares. Credit Suisse Group set a $151.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Friday, July 13th. Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research note on Thursday, July 12th. Sanford C. Bernstein started coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They set a “market perform” rating and a $129.00 target price for the company. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Saturday, July 28th. Finally, Jefferies Financial Group set a $145.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, July 15th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $142.34.

The company has a current ratio of 1.65, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. The company has a market cap of $371.61 billion, a price-to-earnings ratio of 19.16, a price-to-earnings-growth ratio of 2.11 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The firm had revenue of $20.83 billion during the quarter, compared to the consensus estimate of $20.39 billion. During the same period in the previous year, the firm posted $1.83 earnings per share. The business’s revenue was up 10.6% compared to the same quarter last year. equities analysts predict that Johnson & Johnson will post 8.14 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 11th. Shareholders of record on Tuesday, August 28th were paid a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.57%. The ex-dividend date was Monday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 49.32%.

In other news, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the transaction, the chief operating officer now directly owns 59,124 shares in the company, valued at $7,969,915.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction dated Friday, September 7th. The shares were sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the transaction, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Opus Capital Group LLC boosted its holdings in Johnson & Johnson by 5.9% during the fourth quarter. Opus Capital Group LLC now owns 9,544 shares of the company’s stock worth $1,333,000 after purchasing an additional 531 shares during the last quarter. Puzo Michael J boosted its holdings in Johnson & Johnson by 16.9% during the fourth quarter. Puzo Michael J now owns 95,275 shares of the company’s stock worth $13,313,000 after purchasing an additional 13,747 shares during the last quarter. Public Employees Retirement Association of Colorado boosted its holdings in Johnson & Johnson by 7.1% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 512,988 shares of the company’s stock worth $71,675,000 after purchasing an additional 34,230 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in Johnson & Johnson by 0.8% during the fourth quarter. Meeder Asset Management Inc. now owns 66,527 shares of the company’s stock worth $9,295,000 after purchasing an additional 512 shares during the last quarter. Finally, Notis McConarty Edward boosted its holdings in Johnson & Johnson by 3.3% during the fourth quarter. Notis McConarty Edward now owns 55,542 shares of the company’s stock worth $7,760,000 after purchasing an additional 1,780 shares during the last quarter. Hedge funds and other institutional investors own 66.80% of the company’s stock.

Johnson & Johnson Company Profile (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.